Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
Karen-Lise Garm Spindler, Morten Sørensen, Niels Pallisgaard, Rikke Andersen, Birgitte Mayland Havelund, John Ploen, Ulrik Lassen, Leif Anders Jakobsen
Dyk ned i forskningsemnerne om 'Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma'. Sammen danner de et unikt fingeraftryk.